Treatment(s) already received-None Posts on Medivizor
Navigation Menu

Treatment(s) already received-None Posts on Medivizor

Surgery followed by chemotherapy improves the outcomes of patients with rectal cancer

Posted by on Oct 13, 2019 in Colorectal cancer | 0 comments

In a nutshell This study investigated the effectiveness of surgery followed by chemotherapy without chemoradiotherapy (CRT) before surgery to treat rectal cancer. Researchers suggested that this treatment improves the outcomes of these patients.  Some background Colorectal cancer is the third most common cancer worldwide. The standard...

Read More

Evaluating the long-term outcomes of breast-conserving therapy for women with ductal carcinoma in situ.

Posted by on Sep 30, 2019 in Breast cancer | 0 comments

In a nutshell This study wanted to find out what the long-term outcomes were for women with ductal carcinoma in situ (DCIS) who had breast-conserving therapy. The study found that after 10 years, the risk of recurrence of cancer in the same breast was very low.  Some background There are a number of treatment options for DCIS. Some women opt...

Read More

Comparison between two standard treatments for transplant-ineligible multiple myeloma

Posted by on Aug 2, 2019 in Multiple Myeloma | 0 comments

In a nutshell This study investigated whether a combination of bortezomib (Velcade), melphalan (Alkeran) and prednisone (Deltasone) was more effective than lenalidomide (Revlimid) and dexamethasone (Decadron) followed by lenalidomide maintenance for newly diagnosed multiple myeloma (MM). The main finding was that age and disease risk influenced the...

Read More

Searching for patients to try combinations of treatments for newly diagnosed multiple myeloma.

Posted by on Jul 29, 2019 in Multiple Myeloma | 0 comments

In a nutshell This study is looking for patients with newly diagnosed multiple myeloma (MM) to try different treatment regimens. The main outcome that will be measured is the number of patients who do not experience cancer worsening after treatment. This trial is recruiting in Chicago, Illinois, United States. The details There are several...

Read More

Is RTXM83 as effective as rituximab for patients with diffuse large B-cell lymphoma?

Posted by on Jul 28, 2019 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study compared RTXM83 to rituximab (Rituxan) to see if it is as effective and safe for patients with diffuse large B-cell lymphoma.  This study concluded that RTXM83 is as effective and safe as rituximab. Some background Diffuse large B-cell lymphoma (DLBCL) is an aggressive type of non-Hodgkin’s lymphoma.  This type...

Read More

Searching for patients with untreated small lymphocytic lymphoma to test combined immunotherapy

Posted by on Jun 29, 2019 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This phase 2 study is evaluating the effectiveness of a new combination therapy for small lymphocytic lymphoma (SLL). The main outcome to be measured will be the number of patients who have a complete disappearance of all signs of cancer. This study is recruiting in Rochester, New York, US. The details Typical treatments for SLL include...

Read More

Looking for patients to try a treatment combination for untreated chronic lymphocytic leukemia.

Posted by on May 28, 2019 in Leukemia | 0 comments

In a nutshell This study is searching for patients with previously untreated chronic lymphocytic leukemia (CLL) to try a new treatment combination containing obinutuzumab (Gazyva) or obinutuzumab/bendamustine (Treanda) to shrink the tumor (debulking) before treatment with venetoclax (Venclexta). The main outcome that will be measured is the number...

Read More

Is vascular-targeted photodynamic therapy or active surveillance more effective in the treatment of low-risk prostate cancer?



Posted by on Apr 30, 2019 in Prostate cancer | 0 comments

In a nutshell This study examined if vascular-targeted photodynamic therapy (VTPT), or active surveillance is more effective in the treatment of low-risk prostate cancer. This study concluded that patients who received VTPT were less likely to require radical therapy compared to those who underwent active surveillance.  Some background...

Read More

Looking for patients with hormone-receptor positive breast cancer to test a new treatment combination

Posted by on Apr 24, 2019 in Breast cancer | 0 comments

In a nutshell This phase 2 trial will investigate the safety of durvalumab (Imfinzi) in combination with standard hormonal treatment for breast cancer (BC). The main outcome will be the response to treatment. The trial is recruiting in Tampa, Florida, US. The details Breast cancer (BC) is one of the most common cancers. It affects bothe...

Read More